FDA recalls Akorn ophthalmic ointment for manufacturing process deviations
Akorn, Inc. is recalling 2,082 tubes of Neomycin and Polymyxin B Sulfates, and Bacitracin Zinc Ophthalmic Ointment nationwide due to manufacturing process deviations. The recall is voluntary and initiated by the manufacturer.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II voluntary recall initiated by the manufacturer. The source text does not identify a specific hazard or report any illnesses or injuries. Manufacturing process deviations without identified consequences fall under the 'voluntary precautionary recalls' category, warranting a Moderate severity rating.
Plain-English summary
Akorn, Inc., based in Lake Forest, Illinois, is recalling 2,082 tubes of Neomycin and Polymyxin B Sulfates, and Bacitracin Zinc Ophthalmic Ointment, USP (3.5 g / 1/8 oz. size, NDC 17478-235-35). The affected lot is Lot 1K64A with an expiration date of September 30, 2023, and was distributed nationwide throughout the United States.
The product is a prescription ophthalmic ointment used to treat eye infections. The FDA classified this as a Class II recall. The recall was voluntary and initiated by Akorn, Inc. on October 13, 2022.
The recall was issued in response to Current Good Manufacturing Practice (CGMP) deviations identified in the manufacturing process.
The recalled product
- Product
- Neomycin and Polymyxin B Sulfates, and Bacitracin Zinc Ophthalmic Ointment, USP, Net Wt. 3.5 g (1/8 oz.), Rx Only, Manufactured by: Akorn, INC., Lake Forest, IL 60045. NDC: 17478-235-35
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Ophthalmic
- Hazard
- cgmp-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot: Lot 1K64A
- EXP 9/30/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27